The safety and efficacy was established by 3 double blind, placebo-controlled studies which included 72 pediatric patients 12 - 16 years old exposed to perampanel The safety and effectiveness in pediatric patients <12 years old have not been established Most common adverse reactions in adult and pediatric patients include dizziness, somnolence, fatigue, irritability, falls, nausea, weight gain, vertigo, ataxia, gait disturbance, and balance disorder Information on clinical trials, dosing, adverse reactions, and pharmacokinetics New drug
|